[go: up one dir, main page]

AR064456A1 - Anticuerpos cd 44 - Google Patents

Anticuerpos cd 44

Info

Publication number
AR064456A1
AR064456A1 ARP070105733A ARP070105733A AR064456A1 AR 064456 A1 AR064456 A1 AR 064456A1 AR P070105733 A ARP070105733 A AR P070105733A AR P070105733 A ARP070105733 A AR P070105733A AR 064456 A1 AR064456 A1 AR 064456A1
Authority
AR
Argentina
Prior art keywords
antibodies
human
compositions
refers
methods
Prior art date
Application number
ARP070105733A
Other languages
English (en)
Original Assignee
Pfizer
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Medarex Inc filed Critical Pfizer
Publication of AR064456A1 publication Critical patent/AR064456A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente se refiere a anticuerpos que incluyen anticuerpos humanos y porciones de los mismos enlazantes al antígeno, que se enlazan a CD44, y que funcionan para inhibir CD44. La solicitud también se refiere a inmunoglobulinas de cadena pesada y ligera derivadas de los anticuerpos CD44 humanos y moléculas de ácido nucleico que codifican tales inmunoglobulinas. La presente también se refiere a métodos para elaborar anticuerpos CD44 humanos, composiciones que comprenden estos anticuerpos y métodos para usar los anticuerpos y composiciones o medicamentos para tratamiento.
ARP070105733A 2006-12-21 2007-12-19 Anticuerpos cd 44 AR064456A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87610906P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
AR064456A1 true AR064456A1 (es) 2009-04-01

Family

ID=39563077

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105733A AR064456A1 (es) 2006-12-21 2007-12-19 Anticuerpos cd 44

Country Status (16)

Country Link
US (1) US20100092484A1 (es)
EP (1) EP2102238A4 (es)
JP (1) JP2010512790A (es)
KR (1) KR20090094848A (es)
CN (1) CN101605812A (es)
AR (1) AR064456A1 (es)
AU (1) AU2007338844A1 (es)
BR (1) BRPI0720477A2 (es)
CA (1) CA2672916A1 (es)
CL (1) CL2007003807A1 (es)
MX (1) MX2009006891A (es)
PE (1) PE20081478A1 (es)
RU (1) RU2009128064A (es)
TW (1) TW200846365A (es)
UY (1) UY30776A1 (es)
WO (1) WO2008079246A2 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8231872B2 (en) * 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
JP2012519710A (ja) * 2009-03-06 2012-08-30 アングストロム プハルマセウトイカルス インコーポレイテッド 細胞遊走を調整するための組成物、及び方法
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2012142238A2 (en) * 2011-04-12 2012-10-18 Duke University Compositions and methods for the treatment of tissue fibrosis
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP2788024A1 (en) * 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
CN103288958B (zh) * 2013-03-22 2015-03-04 暨南大学 抗癌症干细胞特异性蛋白cd44的单链抗体及其应用
JP6474404B2 (ja) 2013-08-14 2019-02-27 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
AU2014363987A1 (en) * 2013-12-09 2016-06-30 Janssen Biotech, Inc. Compositions and methods for phagocyte delivery of anti-staphylococcal agents
CA3090240A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
TW201632532A (zh) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 伸雜芳基－橋聯苯并二氮呯二聚體，其共軛物及製造及使用方法
CN113908257A (zh) 2015-01-26 2022-01-11 卢布里斯有限责任公司 Prg4作为抗炎剂的应用
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
EP3307771A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US10800844B2 (en) 2015-10-29 2020-10-13 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
EA201891482A1 (ru) 2015-12-21 2018-12-28 Бристол-Маерс Сквибб Компани Модифицированные антитела для сайт-специфической конъюгации
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
WO2017196598A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
EP3500574B1 (en) 2016-08-19 2021-11-24 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
KR102650524B1 (ko) 2016-12-09 2024-03-26 알렉터 엘엘씨 항-sirp-알파 항체 및 그의 사용 방법
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
KR20240149979A (ko) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
CA3102086A1 (en) 2017-06-06 2018-12-13 Relinia, Inc. Single-chain tnf receptor 2 agonist fusion proteins
PE20200148A1 (es) 2017-08-03 2020-01-17 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
CN119431582A (zh) 2017-12-29 2025-02-14 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
CA3098710A1 (en) 2018-05-25 2019-11-28 Alector Llc Anti-sirpa antibodies and methods of use thereof
AU2019277094B2 (en) 2018-05-29 2025-12-18 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
BR112020024919A2 (pt) 2018-06-08 2021-03-09 Alector Llc Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica
AU2019293589A1 (en) 2018-06-29 2021-01-21 Alector Llc Anti-SIRP-beta1 antibodies and methods of use thereof
PE20211604A1 (es) 2018-07-09 2021-08-23 Five Prime Therapeutics Inc Anticuerpos de union a ilt4
EP4212210A1 (en) 2018-07-13 2023-07-19 Alector LLC Anti-sortilin antibodies and methods of use thereof
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020047374A1 (en) 2018-08-31 2020-03-05 Alector Llc Anti-cd33 antibodies and methods of use thereof
SG11202103907PA (en) * 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
HUE062089T2 (hu) 2018-11-30 2023-09-28 Rao Naik Chetana Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102259298B1 (ko) * 2019-05-15 2021-05-31 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
EP4003519A2 (en) 2019-07-31 2022-06-01 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
AU2020397888A1 (en) 2019-12-05 2022-06-09 Alector Llc Methods of use of anti-TREM2 antibodies
AU2020403021A1 (en) 2019-12-12 2022-06-23 Alector Llc Methods of use of anti-CD33 antibodies
AU2020401319A1 (en) 2019-12-13 2022-06-30 Alector Llc Anti-MerTK antibodies and methods of use thereof
WO2021173565A1 (en) 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
JP2023520516A (ja) 2020-04-03 2023-05-17 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
ES2988406T3 (es) 2020-05-19 2024-11-20 Inst Curie Antagonistas de la ruta de CD44/ácido hialurónico para su uso en un método para el tratamiento del síndrome de liberación de citocinas
CA3179428A1 (en) * 2020-05-22 2021-11-25 Michael Simons Methods and compositions to treat vascular leak
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
AU2021392039A1 (en) 2020-12-02 2023-06-29 Alector Llc Methods of use of anti-sortilin antibodies
EP4308606A1 (en) 2021-03-18 2024-01-24 Alector LLC Anti-tmem106b antibodies and methods of use thereof
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
MX2023013791A (es) 2021-05-18 2024-02-13 Janssen Biotech Inc Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44.
JP2024527262A (ja) 2021-06-16 2024-07-24 アレクトル エルエルシー 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
US20240279358A1 (en) 2021-06-16 2024-08-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
IL314896A (en) 2022-02-23 2024-10-01 Alector Llc Methods of use of anti-trem2 antibodies
IL317690A (en) 2022-07-29 2025-02-01 Alector Llc Anti-GPNMB antibodies and methods of using them
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024093147A1 (zh) * 2022-10-31 2024-05-10 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025188693A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Bicyclic tlr7 agonists and uses thereof
US20250282786A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Tricyclic TLR7 Agonists and Uses Thereof
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025245176A1 (en) 2024-05-22 2025-11-27 Bristol-Myers Squibb Company Multispecific antibody constructs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543594A (en) * 1992-10-30 1994-05-24 Duke University An adhesion molecule
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU2001292943A1 (en) * 2000-09-21 2002-04-02 The Brigham And Women's Hospital, Inc. Prevention and treatment of streptococcal and staphylococcal infection
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
WO2005087264A1 (en) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury

Also Published As

Publication number Publication date
BRPI0720477A2 (pt) 2014-01-14
EP2102238A4 (en) 2010-09-01
US20100092484A1 (en) 2010-04-15
WO2008079246A2 (en) 2008-07-03
CA2672916A1 (en) 2008-07-03
KR20090094848A (ko) 2009-09-08
WO2008079246A3 (en) 2009-01-08
CL2007003807A1 (es) 2008-05-09
TW200846365A (en) 2008-12-01
CN101605812A (zh) 2009-12-16
UY30776A1 (es) 2008-07-03
PE20081478A1 (es) 2008-12-07
JP2010512790A (ja) 2010-04-30
MX2009006891A (es) 2009-08-28
AU2007338844A1 (en) 2008-07-03
RU2009128064A (ru) 2011-01-27
EP2102238A2 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
AR064456A1 (es) Anticuerpos cd 44
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
UY37223A (es) Anticuerpos de p-caderina
CR10563A (es) Anticuerpos monoclonales ant-il-6 y usos de los mismos
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
EA200602210A1 (ru) Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA200800812A1 (ru) Композиции антитела против cd3
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
MX2010007406A (es) Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119

Legal Events

Date Code Title Description
FB Suspension of granting procedure